Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | BCHE | P06276 | 5/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21198785 | 1.00 | PDCD1 (0.50) | PDCD1CD274CYP3A4CYP2D6TSHR | |
| SCHEMBL21198792 | 0.91 | PDCD1 (0.59) | PDCD1CD274CYP3A4CYP2D6TSHR | |
| SCHEMBL21198778 | 0.83 | PDCD1 (0.49) | PDCD1CD274CYP3A4CYP2D6TSHR | |
| SCHEMBL21198779 | 0.83 | PDCD1 (0.49) | PDCD1CD274CYP3A4CYP2D6TSHR | |
| SCHEMBL21206406 | 0.77 | PDCD1 (0.54) | PDCD1CD274CYP3A4CYP2D6TSHR | |
| SCHEMBL14662696 | 0.76 | OPRM1 (0.46) | KLK7PRMT5SCD5 | |
| SCHEMBL12607067 | 0.75 | PRMT5 (0.56) | KLK7PRMT5WDR77 | |
| SCHEMBL12607070 | 0.75 | PRMT5 (0.56) | KLK7PRMT5WDR77 | |
| SCHEMBL29117319 | 0.75 | PRMT5 (0.56) | KLK7PRMT5WDR77 | |
| SCHEMBL20503925 | 0.75 | JAK2 (0.55) | BCHEKLK7PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3743425-B1 | 2,8-DIACYL-2,8-DIAZASPIRO[5.5]UNDECANE COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11414418-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-16 | — | — | US | disclosed |
| US-20210053972-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| US-20210053972-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2021-02-25 | — | — | US | disclosed |
| EP-3743425-A1 | 2,8-DIACYL-2,8-DIAZASPIRO[5.5]UNDECANE COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019147662-A1 | 2,8-DIACYL-2,8-DIAZASPIRO[5.5]UNDECANE COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
| WO-2019147662-A1 | 2,8-DIACYL-2,8-DIAZASPIRO[5.5]UNDECANE COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053972-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | PDCD1 161/4885CD274 52/4885CYP3A4 3478/4885 |
| US-11414418-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | PDCD1 161/4885CD274 52/4885CYP3A4 3478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.